磷脂酰肌醇蛋白聚糖3基因与肝癌关系的研究进展  

The progress relationship between hepatocellular carcinoma and Glypican-3

作　　者：吕庆杰[1] 刘剑勇[1] 

机构地区：[1]广西医科大学附属肿瘤医院肝胆外科,南宁530021

出　　处：《国际免疫学杂志》2013年第4期268-270,共3页International Journal of Immunology

基　　金：广西医疗卫生重点科研课题（重200611）;广西科学研究与技术开发计划项目（桂科攻0719006-2-5）;广西科学基金项目（桂科自0728196）

摘　　要：原发性肝癌（PHC）是目前世界上最常见的恶性肿瘤之一。肝癌的发生是由化学致癌物、病毒、遗传等多病因作用引起的。其恶性程度高，预后差，进展较快。早期诊断、治疗对肝癌患者的预后至关重要，目前临床诊断主要依靠影像学检查及肿瘤标志物甲胎蛋白（AFP）。但AFP的敏感性和特异性均不高。近年来，一种新的肝癌肿瘤学标志物磷脂酰肌醇蛋白聚糖3（GPC3）成为不少国内外学者研究热点，其在肝癌中无论mRNA水平还是蛋白质水平均为高表达，GPC3对PHC的诊断具有较高的敏感性和特异性，其在AFP阴性的肝癌中亦有表达。Primary hepatic carcinoma （PHC） is one of the most common malignancy detection of in the world. There are many etiologys can arouse PHC ： chemical carcinogens, virus, inheritance, etc. PHC shows a high malignant degree, poor prognosis and fast progress. Early diagnosis and treatment of PHC is very important for the prognosis of patients, present, clinical diagnosis mainly depends on imaging examinations and the detec- tion of tumor marker：alpha fetal protein （AFP）. However, the sensitivity and specificity of AFP was not satis- fied. In recent years, a new tumor marker, glypican-3 （GPC3） has been extensively sttedied. Its mRNA and protein levels in PHC were highly expressed. Detection of GPC3 has higher sensitivity and specificity for the di- agnosis of PHC. GPC3 is also expressed in the PHC patients with negative AFP.

关 键 词：磷脂酰肌醇蛋白聚糖3 肿瘤标志物 基因治疗 

分 类 号：R735.7[医药卫生—肿瘤]